Discovery and Preclinical Characterization of Benzofuran Derivatives as Potent, Selective, and Orally Bioavailable GSPT1 Molecular Glue Degraders for the Treatment of MYC-Driven Cancers
Abstract Targeted protein degradation of the translation termination factor GSPT1 is a promising cancer strategy. However, current cereblon-recruiting molecular glue degraders (MGDs) lack structural diversity, being mostly IMiD derivatives. To overcome resistance and improve drug-like properties, we report the rational, structure-guided design of a novel series of benzofuran-based GSPT1 MGDs. Extensive structure−activity relationship studies and optimization led to the discovery of highly potent, orally bioavailable degraders, highlighted by compounds C-3 and C-4. Both exhibited single-digit nanomolar GSPT1 degradation (DC50 = 2.81 and 1.91 nM) and robust selectivity over IMiD off-targets IKZF1 and SALL4. In vivo, oral administration (1−2 mg/kg) of C-3 and C-4 demonstrated favorable cross-species pharmacokinetics and achieved sustained tumor regression in NCI-H1155 and MDA-MB-468 xenograft models. With a maximum tolerated dose exceeding 100 mg/kg and no hematological toxicity, these benzofuran-based MGDs are highly promising preclinical candidates for solid tumors.
Authors
- Cancan Cai
- Yujie Chang (ORCID: https://orcid.org/0009-0000-5051-2459)
- Mengting Zhao (ORCID: https://orcid.org/0000-0002-8956-6873)
- Zhimin Zhang (ORCID: https://orcid.org/0000-0002-9394-9586)
- Li Teng
- Dongzhou Liu
- Xiaoyan Deng
- Jiangqi He
- Xiaohua Zhang
- Jingwen E
Institutions
- Zhejiang Sci-Tech University (CN)
- Powerchina Huadong Engineering Corporation (China) (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c01738
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00